139 related articles for article (PubMed ID: 29223988)
41. One in two cancer patients is significantly distressed: Prevalence and indicators of distress.
Mehnert A; Hartung TJ; Friedrich M; Vehling S; Brähler E; Härter M; Keller M; Schulz H; Wegscheider K; Weis J; Koch U; Faller H
Psychooncology; 2018 Jan; 27(1):75-82. PubMed ID: 28568377
[TBL] [Abstract][Full Text] [Related]
42. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.
Geyer HL; Dueck AC; Scherber RM; Mesa RA
Mediators Inflamm; 2015; 2015():284706. PubMed ID: 26538823
[TBL] [Abstract][Full Text] [Related]
43. Screening for distress, the sixth vital sign, in lung cancer patients: effects on pain, fatigue, and common problems--secondary outcomes of a randomized controlled trial.
Carlson LE; Waller A; Groff SL; Bultz BD
Psychooncology; 2013 Aug; 22(8):1880-8. PubMed ID: 23147718
[TBL] [Abstract][Full Text] [Related]
44. Disabled, invisible and dismissed-The lived experience of fatigue in people with myeloproliferative neoplasms.
Bradford A; Young K; Whitechurch A; Burbury K; Pearson EJM
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1655. PubMed ID: 35705529
[TBL] [Abstract][Full Text] [Related]
45. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark.
Brochmann N; Flachs EM; Christensen AI; Bak M; Andersen CL; Juel K; Hasselbalch HC; Zwisler AD; Rottmann N
Clin Epidemiol; 2019; 11():23-33. PubMed ID: 30588121
[TBL] [Abstract][Full Text] [Related]
46. Patient-reported distress and problems among elderly patients with hematological malignancy in Korea.
Park SY; Kim Y; Hong H
Support Care Cancer; 2022 Nov; 30(11):9019-9027. PubMed ID: 35948847
[TBL] [Abstract][Full Text] [Related]
47. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Langlais BT; Mazza GL; Kosiorek HE; Palmer J; Mesa R; Dueck AC
J Hematol; 2021 Oct; 10(5):207-211. PubMed ID: 34804309
[TBL] [Abstract][Full Text] [Related]
48. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
[TBL] [Abstract][Full Text] [Related]
49. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.
Jentsch-Ullrich K; Eberhardt J; Zeremski V; Koehler M; Wolleschak D; Heidel FH
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2041-9. PubMed ID: 27431664
[TBL] [Abstract][Full Text] [Related]
50. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
51. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
Radia D; Geyer HL
Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
[TBL] [Abstract][Full Text] [Related]
52. Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy.
Yamagishi A; Morita T; Miyashita M; Kimura F
J Pain Symptom Manage; 2009 May; 37(5):823-30. PubMed ID: 18804946
[TBL] [Abstract][Full Text] [Related]
53. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
54. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
55. [Myeloproliferative neoplasms related glomerulopathy].
Paule R; Ponsoye M; Gueutin V; Deray G; Izzedine H
Rev Med Interne; 2013 Jun; 34(6):369-72. PubMed ID: 23357690
[TBL] [Abstract][Full Text] [Related]
56. Chronic myeloproliferative diseases.
de Lacerda JF; Oliveira SN; Ferro JM
Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
[TBL] [Abstract][Full Text] [Related]
57. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.
Mazza GL; Kunze KL; Langlais BT; Kosiorek HE; DeWees TA; Geyer HL; Scherber RM; Mesa RA; Dueck AC
Leuk Lymphoma; 2019 Jul; 60(7):1789-1795. PubMed ID: 30652523
[TBL] [Abstract][Full Text] [Related]
58. Distress and its correlates in Korean cancer patients: pilot use of the distress thermometer and the problem list.
Shim EJ; Shin YW; Jeon HJ; Hahm BJ
Psychooncology; 2008 Jun; 17(6):548-55. PubMed ID: 17957764
[TBL] [Abstract][Full Text] [Related]
59. Selected parameters of hemostasis in patients with myeloproliferative neoplasms.
Gadomska G; Rość D; Stankowska K; Boinska J; Ruszkowska-Ciastek B; Wieczór R
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):464-70. PubMed ID: 24509338
[TBL] [Abstract][Full Text] [Related]
60. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
